Adcock Ingram Adcock Ingram is a leading, world-class healthcare company Access all company related information including information related to the Company’s brands, investor related information, latest news, corporate social responsibility initiatives and more
FOR THE YEAR ENDED 30 JUNE 2024 - adcock. com Adcock Ingram is on a journey to make ESG Sustainability data more transparent for our stakeholders This includes improvements to various policies, procedures, systems and controls, which resulted in an improvement in our ability to measure and report our performance This also led to an improvement in the amount of data included since last year,
Adcock Ingram Adcock Ingram Gastroenterology medication addresses the needs of patients with Ulcerative colitis Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the large intestine and rectum 1 It is one of a group of diseases known as inflammatory bowel disease 1
Integrated report - Adcock Adcock Ingram’s integrated report covers the financial year 1 July 2017 to 30 June 2018 The report is released at least 15 business days prior to its Annual General Meeting to be held on 22 November 2018 Comparatives are for the year 1 July 2016 to 30 June 2017 The report provides a general narrative on the
2022 Integrated Report - Adcock Adcock Ingram’s Integrated Report covers the financial year 1 July 2021 to 30 June 2022 Comparatives are for the year 1 July 2020 to 30 June 2021 and included where available The report is released at least 15 business days prior to the Company’s Annual General Meeting to be held on 22 November 2022
SCHEDULING STATUS S2 - adcock. com Risk of fracture Proton pump inhibitors, such as RAPACID 20, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist, and spine fracture,
GROUP ANNUAL RESULTS AND CASH DIVIDEND DECLARATION - Adcock The Group increased its treasury shares held by Adcock Ingram Limited (AIL) by an additional 9 2 million during the current year, at an average cost of R51 16 per share, resulting in a cash outflow of R472 1 million
Group annual results and cash dividend declaration - Adcock Adcock Ingram’s strong and adaptable people, and diverse portfolios have proved beneficial in this unprecedented operating environment In addition, these results could not have been achieved without the
www. adcock. com Cash flows Audited Year ended R’000 Cash flows from operating activities Operating profit before working capital changes Working capital changes Cash generated from operations